Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Syndax Pharmaceuticals ( (SNDX) ) is now available.
On June 24, 2025, William Meury resigned from the Board of Directors of Syndax Pharmaceuticals to become the President and CEO at Incyte Corporation, a partner for Niktimvo™. His resignation was effective immediately and was not due to any disagreements with Syndax Pharmaceuticals.
The most recent analyst rating on (SNDX) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Syndax Pharmaceuticals stock, see the SNDX Stock Forecast page.
Spark’s Take on SNDX Stock
According to Spark, TipRanks’ AI Analyst, SNDX is a Neutral.
Syndax Pharmaceuticals faces significant risks due to declining revenues, persistent losses, and negative cash flows, which weigh heavily on its overall score. While the balance sheet remains strong with low leverage, the technical indicators suggest a bearish trend. The valuation is unattractive due to negative earnings. Despite these challenges, the recent earnings call provided some positive news with product launches and a strengthened financial position, partially offsetting the negative aspects. Overall, the company’s ability to improve financial performance and achieve market penetration in the face of competition will be crucial for future stock performance.
To see Spark’s full report on SNDX stock, click here.
More about Syndax Pharmaceuticals
Syndax Pharmaceuticals operates in the pharmaceutical industry, focusing on developing and commercializing therapies for cancer treatment. The company collaborates with partners like Incyte Corporation to advance its product offerings, such as Niktimvo™ (axatilimab-csfr).
Average Trading Volume: 2,253,236
Technical Sentiment Signal: Sell
Current Market Cap: $765.8M
Find detailed analytics on SNDX stock on TipRanks’ Stock Analysis page.